RT Journal Article
SR Electronic
T1 Human influenza virus infection elicits distinct patterns of monocyte and dendritic cell mobilization in blood and the nasopharynx
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.18.22269508
DO 10.1101/2022.01.18.22269508
A1 Vangeti, S.
A1 Falck-Jones, S.
A1 Yu, M.
A1 Österberg, B.
A1 Liu, S.
A1 Asghar, M.
A1 Sondén, K.
A1 Albert, J.
A1 Johansson, N.
A1 Färnert, A.
A1 Smed-Sörensen, A.
YR 2022
UL http://medrxiv.org/content/early/2022/02/10/2022.01.18.22269508.abstract
AB During respiratory viral infections, the precise roles of monocytes and dendritic cells (DCs) in the nasopharynx in limiting infection and influencing disease severity are incompletely described. We studied circulating and nasopharyngeal monocytes and DCs in healthy individuals and in patients with mild respiratory infections (primarily influenza A virus, IAV). As compared to healthy controls (HCs), patients with acute IAV infection displayed reduced DC but increased intermediate monocytes frequencies in blood, and an accumulation of most monocyte and DC subsets in the nasopharynx. IAV patients had more mature monocytes and DCs in the nasopharynx, and higher levels of TNFα, IL-6 and IFNα in plasma and the nasopharynx. In blood, monocytes, the most frequent cellular source of TNFα during IAV infection, remained responsive to additional stimulation with TLR7/8L. Immune responses in older patients skewed towards increased monocytes rather than DCs suggesting a contributory role for monocytes in disease severity. In patients with other respiratory virus infections, we observed changes in monocyte and DC frequencies in the nasopharynx distinct from IAV patients, while differences in blood were more similar across patient groups. Together, our findings demonstrate tissue-specific and pathogen-specific patterns of monocyte and DC function during human respiratory viral infections and highlight the importance of comparative investigations in blood and the nasopharynx.Competing Interest StatementAS-S is a consultant to Astra-Zeneca on studies not related to the present study.Funding StatementThis work was supported by grants to AS-S from the Swedish Research Council (VR), the Swedish Heart-Lung Foundation, the Bill and Melinda Gates Foundation, the Swedish Childhood Cancer Fund and Karolinska Institutet.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority (No. 2015/1949-31/4) and performed according to the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.